Alexion receives orphan drug designation for Soliris

theflyonthewall.com

Alexion Pharmaceuticals announced that Soliris, the company's first-in-class terminal complement inhibitor, has been granted an orphan drug designation by the U.S. FDA for the treatment of neuromyelitis optica, a life-threatening, ultra-rare neurological disorder. In a Phase 2 study presented at the 2012 annual meeting of the American Neurological Association, Soliris treatment was associated with a significant reduction in the frequency of relapses in patients with severe, relapsing NMO.1. Soliris is not approved for the treatment of patients with NMO.

View Comments (0)